Exploring the Potential of Eltrombopag: Room for More?

Overview

Journal Front Pharmacol

Date 2022 Jun 9

PMID 35677428

Authors

Francesco Tarantini

Cosimo Cumbo

Luisa Anelli

Antonella Zagaria

Maria Rosa Conserva

Immacolata Redavid

Giorgina Specchia

Pellegrino Musto

Francesco Albano

Affiliations

Soon will be listed here.

Abstract

Since its introduction in clinical practice, eltrombopag (ELT) has demonstrated efficacy in heterogeneous clinical contexts, encompassing both benign and malignant diseases, thus leading researchers to make a more in-depth study of its mechanism of action. As a result, a growing body of evidence demonstrates that ELT displays many effects ranging from native thrombopoietin agonism to immunomodulation, anti-inflammatory, and metabolic properties. These features collectively explain ELT effectiveness in a broad spectrum of indications; moreover, they suggest that ELT could be effective in different, challenging clinical scenarios. We reviewed the extended ELT mechanism of action in various diseases, with the aim of further exploring its full potential and hypothesize new, fascinating indications.

Citing Articles

Effects of genetic ablation and pharmacological inhibition of HuR on gene expression, iron metabolism, and hormone levels.

Idlin N, Krishnamoorthy S, Wolczyk M, Fakhri M, Lechowski M, Stec N BMC Biol. 2025; 23(1):24.

PMID: 39849491 PMC: 11756078. DOI: 10.1186/s12915-025-02131-z.

Impact of Serum Ferritin and Iron Overload on Acute Myeloid Leukemia Outcomes: A Systematic Review and Meta-Analysis.

Sadighi S, Sahinoglu E, Haider Kubba A, Patel J, Hosseini S, Shafiee M Asian Pac J Cancer Prev. 2024; 25(8):2951-2962.

PMID: 39205594 PMC: 11495433. DOI: 10.31557/APJCP.2024.25.8.2951.

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.

Zhang Y, Li J, Li X, Geng Q, Xie Y, Zhang G Syst Rev. 2024; 13(1):101.

PMID: 38576005 PMC: 10993616. DOI: 10.1186/s13643-024-02515-2.

All Roads Lead to Interferon-γ: From Known to Untraveled Pathways in Acquired Aplastic Anemia.

Serio B, Giudice V, Selleri C Medicina (Kaunas). 2023; 59(12).

PMID: 38138273 PMC: 10744863. DOI: 10.3390/medicina59122170.

[Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)].

Zhonghua Xue Ye Xue Za Zhi. 2023; 44(7):535-542.

PMID: 37749031 PMC: 10509622. DOI: 10.3760/cma.j.issn.0253-2727.2023.07.002.

References

Raslova H, Vainchenker W, Plo I . Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica. 2016; 101(12):1443-1445. PMC: 5479610. DOI: 10.3324/haematol.2016.153668. View

Di Buduo C, Currao M, Pecci A, Kaplan D, Balduini C, Balduini A . Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica. 2016; 101(12):1479-1488. PMC: 5479602. DOI: 10.3324/haematol.2016.146746. View

Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M . Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013; 123(12):1818-25. PMC: 3962161. DOI: 10.1182/blood-2013-10-534743. View

Al-Samkari H, Kuter D . An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018; 84(11):2673-2677. PMC: 6177710. DOI: 10.1111/bcp.13717. View

Gilreath J, Lo M, Bubalo J . Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. Drugs. 2021; 81(11):1285-1305. PMC: 8318934. DOI: 10.1007/s40265-021-01553-7. View

Ninos J, Jefferies L, Cogle C, Kerr W . The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med. 2006; 4:9. PMC: 1402332. DOI: 10.1186/1479-5876-4-9. View

Di Paola A, Palumbo G, Merli P, Argenziano M, Tortora C, Strocchio L . Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia. Int J Mol Sci. 2020; 22(1). PMC: 7796119. DOI: 10.3390/ijms22010097. View

Alvarado L, Huntsman H, Cheng H, Townsley D, Winkler T, Feng X . Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019; 133(19):2043-2055. PMC: 6509545. DOI: 10.1182/blood-2018-11-884486. View

Schmiedel B, Singh D, Madrigal A, Valdovino-Gonzalez A, White B, Zapardiel-Gonzalo J . Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell. 2018; 175(6):1701-1715.e16. PMC: 6289654. DOI: 10.1016/j.cell.2018.10.022. View

10.

Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, Kuwana M . Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. Int J Hematol. 2014; 100(4):341-4. DOI: 10.1007/s12185-014-1661-4. View

11.

Sadallah S, Amicarella F, Eken C, Iezzi G, Schifferli J . Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells. Thromb Haemost. 2014; 112(6):1219-29. DOI: 10.1160/TH14-03-0281. View

12.

Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella M . Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018; 132(25):2629-2638. PMC: 6337824. DOI: 10.1182/blood-2018-06-855221. View

13.

Sadallah S, Eken C, Schifferli J . Ectosomes as immunomodulators. Semin Immunopathol. 2010; 33(5):487-95. DOI: 10.1007/s00281-010-0232-x. View

14.

Frey N, Jang J, Szer J, Illes A, Kim H, Ram R . Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019; 6(3):e122-e131. DOI: 10.1016/S2352-3026(18)30231-X. View

15.

Babushok D . A brief, but comprehensive, guide to clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):457-466. PMC: 6245980. DOI: 10.1182/asheducation-2018.1.457. View

16.

Deng Y, Madatian A, Wire M, Bowen C, Park J, Williams D . Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011; 39(9):1734-46. DOI: 10.1124/dmd.111.040170. View

17.

Brynes R, Wong R, Thein M, Bakshi K, Burgess P, Theodore D . A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. Acta Haematol. 2016; 137(2):66-72. DOI: 10.1159/000452992. View

18.

Mahevas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M . The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014; 165(6):865-9. DOI: 10.1111/bjh.12888. View

19.

Spitz A, Zacharioudakis E, Reyna D, Garner T, Gavathiotis E . Eltrombopag directly inhibits BAX and prevents cell death. Nat Commun. 2021; 12(1):1134. PMC: 7892824. DOI: 10.1038/s41467-021-21224-1. View

20.

Schoettler M, Nathan D . The Pathophysiology of Acquired Aplastic Anemia: Current Concepts Revisited. Hematol Oncol Clin North Am. 2018; 32(4):581-594. PMC: 6538304. DOI: 10.1016/j.hoc.2018.03.001. View